Summary
This article reviews the use of clomiphene as an alternative to testosterone replacement therapy (TRT) for men with low testosterone, focusing on its ability to increase endogenous testosterone while preserving fertility. It also outlines appropriate patient selection, mechanism of action, and key considerations for monitoring therapy in men with secondary hypogonadism.
Introduction
Low testosterone, or male hypogonadism, can contribute to fatigue, loss of libido, mood instability, muscle weakness, and difficulty maintaining focus. While testosterone replacement therapy (TRT) is a well-known treatment option, its suppression of the body’s endogenous testosterone and sperm production makes it less suitable for men trying to conceive. Testosterone replacement therapy remains an appropriate treatment for many men with hypogonadism, particularly those not seeking fertility. For men who wish to improve testosterone levels while maintaining fertility, clomiphene may be a physiologically supportive alternative. Key considerations include patient selection, mechanism of action, and monitoring in men with secondary hypogonadism.
CLOMIPHENE AS AN ALTERNATIVE TO TESTOSTERONE REPLACEMENT THERAPY (TRT)
For men who are planning to have children or wish to avoid the reproductive suppression that can occur with exogenous testosterone therapy, clomiphene provides a fertility-preserving alternative. Studies have shown that clomiphene can raise both total and free testosterone levels while maintaining sperm count and motility [1, 2]. One study found increases comparable to those seen with testosterone gels [3]. This makes it a compelling testosterone therapy alternative for younger men or those with secondary hypogonadism.
CLOMIPHENE USE IN SECONDARY HYPOGONADISM
Male hypogonadism can be categorized as either primary or secondary. Primary hypogonadism originates from testicular dysfunction, where the testes are unable to respond to luteinizing hormone (LH) and follicle-stimulating hormone (FSH). As a result, clomiphene is not effective in these cases because the underlying issue is testicular rather than central. Secondary hypogonadism often results from hypothalamic and/or pituitary dysfunction, as well as obesity and Type II Diabetes Mellitus (T2DM) [4].
OBESITY-RELATED HYPOGONADISM
Male obesity is a common contributor to secondary hypogonadism because adipose tissue contains high aromatase activity, which converts testosterone into estradiol and increases circulating estrogen levels. This shift can suppress the hypothalamic-pituitary-gonadal axis and reduce endogenous testosterone production. Clinical studies suggest clomiphene may be a treatment option for male obesity-associated secondary hypogonadism, with randomized trials showing increases in testosterone, gonadotropins, and SHBG. Additionally, improvements were seen in body composition, certain semen parameters, and symptom scores [5].
CLOMIPHENE FOR LOW TESTOSTERONE SYMPTOMS
Androgen deficiency severity in men treated with clomiphene has been assessed using the Androgen Deficiency in Aging Males (ADAM) questionnaire, a 10-question screening tool evaluating symptoms such as libido, erectile function, muscle strength, and energy [6]. Several cohort studies demonstrate that clomiphene therapy improves ADAM scores in men with hypogonadism, with significant reductions in symptom burden after treatment [7-9].
HOW CLOMIPHENE WORKS TO INCREASE TESTOSTERONE
Clomiphene for men works by stimulating the body’s own endocrine system rather than providing external testosterone. As a selective estrogen receptor modulator (SERM), it blocks estrogen receptors in the hypothalamus and pituitary gland. This disruption of estrogen’s feedback loop leads to increased production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which signal the testes to produce more testosterone and maintain spermatogenesis [4]. This process keeps testicular function intact, allowing men to sustain natural fertility while achieving hormonal balance.
MONITORING HORMONES DURING CLOMIPHENE THERAPY
Clomiphene therapy should always be individualized. Optimal dosing varies based on baseline hormone levels and symptom severity. Overstimulation of the hypothalamic-pituitary-gonadal axis can increase estradiol levels, which may cause side effects such as mood changes, gynecomastia, or weight fluctuations [10]. Some men may experience mild visual disturbances or headaches, which typically resolve upon dose adjustment or discontinuation [11]. Total testosterone, free testosterone, LH, FSH, and estradiol should be assessed at baseline, during titration, and twice yearly once stable [7]. Close collaboration between providers and patients is key to achieving optimal outcomes while minimizing risks.
Conclusion
As awareness of male reproductive health continues to grow, many clinicians are re-evaluating treatment strategies that balance hormonal restoration with fertility preservation. Clomiphene offers an evidence-based, fertility-friendly alternative to traditional testosterone replacement, helping men improve energy, libido, and vitality without compromising their ability to conceive.
Carie Boyd Pharmaceuticals offers compounded clomiphene capsules and sublingual drops by prescription, allowing for customized treatment based on individual patient needs.
- Huijben, M.; Huijsmans, R.L.N.; Lock, M.T.W.T.; de Kemp, V.F.; de Kort, L.M.O.; van Breda, J.H.M.K. Clomiphene citrate for male infertility: A systematic review and meta-analysis. Andrology 2023, 11, 987–996.
- Jarow, J.P.; Zirkin, B.R. The Androgen Microenvironment of the Human Testis and Hormonal Control of Spermatogenesis. Ann. N. Y. Acad. Sci. 2005, 1061, 208–220.
- Ramasamy R., Scovell J.M., Kovac J.R., Lipshultz L.I. Testosterone Supplementation Versus Clomiphene Citrate for Hypogonadism: An Age Matched Comparison of Satisfaction and Efficacy. J. Urol. 2014;192:875–879. doi: 10.1016/j.juro.2014.03.089.
- Wu, Y. C., & Sung, W. W. (2024). Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications. Pharmaceuticals (Basel, Switzerland), 17(9), 1233. https://doi.org/10.3390/ph17091233.
- Soares, A.H.; Horie, N.C.; Chiang, L.A.P.; Caramelli, B.; Matheus, M.G.; Campos, A.H.; Marti, L.C.; Rocha, F.A.; Mancini, M.C.; Costa, E.M.F.; et al. Effects of clomiphene citrate on male obesity-associated hypogonadism: A randomized, double-blind, placebo-controlled study. J. Obes.2018, 42, 953–963.
- Morley J.E., Charlton E., Patrick P., Kaiser F.E., Cadeau P., McCready D., Perry H.M., 3rd Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239–1242. doi: 10.1053/meta.2000.8625.
- Katz, D.J.; Nabulsi, O.; Tal, R.; Mulhall, J.P. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int.2012, 110, 573–578.
- Chandrapal, J.C.; Nielson, S.; Patel, D.P.; Zhang, C.; Presson, A.P.; Brant, W.O.; Myers, J.B.; Hotaling, J.M. Characterising the safety of clomiphene citrate in male patients through prostate-specific antigen, haematocrit, and testosterone levels. BJU Int.2016, 118, 994–1000.
- Moskovic, D.J.; Katz, D.J.; Akhavan, A.; Park, K.; Mulhall, J.P. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int. 2012, 110, 1524–1528.
- Wheeler K.M., Sharma D., Kavoussi P.K., Smith R.P., Costabile R. Clomiphene Citrate for the Treatment of Hypogonadism. Sex. Med. Rev. 2019;7:272–276. doi: 10.1016/j.sxmr.2018.10.001.
- Huijben M., Lock M.T.W., de Kemp V.F., de Kort L.M., van Breda H. Clomiphene citrate for men with hypogonadism: A systematic review and meta-analysis. Andrology. 2022;10:451–469. doi: 10.1111/andr.13146.